Shufen Xu

658 total citations · 2 hit papers
17 papers, 419 citations indexed

About

Shufen Xu is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shufen Xu has authored 17 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Cancer Research and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shufen Xu's work include Cancer-related molecular mechanisms research (7 papers), RNA modifications and cancer (5 papers) and Circular RNAs in diseases (4 papers). Shufen Xu is often cited by papers focused on Cancer-related molecular mechanisms research (7 papers), RNA modifications and cancer (5 papers) and Circular RNAs in diseases (4 papers). Shufen Xu collaborates with scholars based in China, Canada and Hong Kong. Shufen Xu's co-authors include Alex Golubovic, Andrew Varley, Yue Xu, Bowen Li, Jingan Chen, Rick Xing Ze Lu, Haotian Cui, Bo Wang, Hao Ji and Songtao Dong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Advanced Materials and Nature Communications.

In The Last Decade

Shufen Xu

17 papers receiving 412 citations

Hit Papers

AGILE platform: a deep learning powered approach to accel... 2024 2026 2025 2024 2024 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery
    2024 91 citations Yue Xu, Shihao Ma et al. Nature Communications profile →
  2. Tumor‐Tailored Ionizable Lipid Nanoparticles Facilitate IL‐12 Circular RNA Delivery for Enhanced Lung Cancer Immunotherapy
    2024 62 citations Shufen Xu, Yue Xu et al. Advanced Materials profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shufen Xu China 12 290 101 55 53 36 17 419
Renfeng Liu China 11 200 0.7× 130 1.3× 46 0.8× 44 0.8× 25 0.7× 17 377
Desmond Pink Canada 11 198 0.7× 83 0.8× 70 1.3× 68 1.3× 64 1.8× 29 395
Marcos Vinícios Salles Dias Brazil 8 252 0.9× 66 0.7× 29 0.5× 42 0.8× 21 0.6× 14 358
Ye Sang China 15 440 1.5× 155 1.5× 73 1.3× 68 1.3× 29 0.8× 27 584
Shahrokh M. Ghobadloo Canada 10 309 1.1× 115 1.1× 83 1.5× 31 0.6× 20 0.6× 13 446
Xue Shan China 10 161 0.6× 102 1.0× 89 1.6× 43 0.8× 14 0.4× 12 335
Marzieh Rezaei Iran 12 155 0.5× 53 0.5× 33 0.6× 67 1.3× 25 0.7× 38 361
Daniel P. Feldmann United States 8 224 0.8× 76 0.8× 48 0.9× 26 0.5× 86 2.4× 10 418
Delphi Van Haver Belgium 12 243 0.8× 84 0.8× 37 0.7× 53 1.0× 32 0.9× 21 420

Countries citing papers authored by Shufen Xu

Since Specialization
Citations

This map shows the geographic impact of Shufen Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shufen Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shufen Xu more than expected).

Fields of papers citing papers by Shufen Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shufen Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shufen Xu. The network helps show where Shufen Xu may publish in the future.

Co-authorship network of co-authors of Shufen Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Shufen Xu. A scholar is included among the top collaborators of Shufen Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shufen Xu. Shufen Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Zhang, Yiqing, Shufen Xu, Jie Li, et al.. (2025). Investigating the role of MicroRNA-519d-3p in enhancing chemosensitivity of colorectal cancer cells to 5-Fluorouracil through PFKFB3 targeting. Clinics. 80. 100606–100606. 1 indexed citations
2.
Xu, Shufen, Yue Xu, Jingan Chen, et al.. (2024). Tumor‐Tailored Ionizable Lipid Nanoparticles Facilitate IL‐12 Circular RNA Delivery for Enhanced Lung Cancer Immunotherapy (Adv. Mater. 29/2024). Advanced Materials. 36(29). 11 indexed citations
3.
Xu, Yue, Shihao Ma, Haotian Cui, et al.. (2024). AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nature Communications. 15(1). 6305–6305. 91 indexed citations breakdown →
4.
Xu, Shufen, Hao Ji, Chao Li, et al.. (2024). m6A modification of lncRNA ABHD11-AS1 promotes colorectal cancer progression and inhibits ferroptosis through TRIM21/IGF2BP2/ FOXM1 positive feedback loop. Cancer Letters. 596. 217004–217004. 23 indexed citations
5.
Xu, Shufen, Yue Xu, Jingan Chen, et al.. (2024). Tumor‐Tailored Ionizable Lipid Nanoparticles Facilitate IL‐12 Circular RNA Delivery for Enhanced Lung Cancer Immunotherapy. Advanced Materials. 36(29). e2400307–e2400307. 62 indexed citations breakdown →
6.
7.
Chen, Jingan, Yue Xu, Shufen Xu, et al.. (2023). Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects. Proceedings of the National Academy of Sciences. 120(50). e2309472120–e2309472120. 76 indexed citations
8.
Xu, Shufen, Yuting Wang, Jie Ding, et al.. (2023). STAT2‐induced linc02231 promotes tumorigenesis and angiogenesis through modulation of hnRNPA1/ANGPTL4 in colorectal cancer. The Journal of Gene Medicine. 25(8). e3506–e3506. 9 indexed citations
9.
Xu, Yue, Haiyan Chen, Shufen Xu, et al.. (2022). β-Lactamase-Responsive Probe for Efficient Photodynamic Therapy of Drug-Resistant Bacterial Infection. ACS Sensors. 7(5). 1361–1371. 12 indexed citations
10.
11.
Ji, Hao, Juan Wang, Binbin Lu, et al.. (2021). SP1 induced long non-coding RNA AGAP2-AS1 promotes cholangiocarcinoma proliferation via silencing of CDKN1A. Molecular Medicine. 27(1). 10–10. 10 indexed citations
12.
Wang, Yuting, Wen Zhang, Lin Chen, et al.. (2021). The ATO/miRNA-885-5p/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma. Cellular Oncology. 44(4). 907–916. 10 indexed citations
13.
Xu, Shufen, et al.. (2021). Human epididymis protein 4 as a new diagnostic biomarker for rheumatoid arthritis-associated interstitial lung disease. Clinical and Experimental Rheumatology. 40(11). 2167–2174. 12 indexed citations
14.
Xu, Yue, Hua Li, Shufen Xu, et al.. (2021). Light-Triggered Fluorescence Self-Reporting Nitric Oxide Release from Coumarin Analogues for Accelerating Wound Healing and Synergistic Antimicrobial Applications. Journal of Medicinal Chemistry. 65(1). 424–435. 26 indexed citations
15.
Xu, Shufen, et al.. (2020). <p>LncRNA MIR503HG Inhibits Non-Small Cell Lung Cancer Cell Proliferation by Inducing Cell Cycle Arrest Through the Downregulation of Cyclin D1</p>. Cancer Management and Research. Volume 12. 1641–1647. 11 indexed citations
16.
Xu, Jianfeng, Wěi Li, Shufen Xu, Weiyang Gao, & Zhenyu Yu. (2019). Effect of dermatan sulphate on a C57-mouse model of pulmonary fibrosis. Journal of International Medical Research. 47(6). 2655–2665. 11 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Renfeng Liu Breakdown of academic impact, for papers by Desmond Pink Breakdown of academic impact, for papers by Marcos Vinícios Salles Dias Breakdown of academic impact, for papers by Ye Sang Breakdown of academic impact, for papers by Shahrokh M. Ghobadloo Breakdown of academic impact, for papers by Xue Shan Breakdown of academic impact, for papers by Marzieh Rezaei Breakdown of academic impact, for papers by Daniel P. Feldmann Breakdown of academic impact, for papers by Delphi Van Haver
Rankless by CCL
2026